Lantz Financial LLC increased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 14.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,672 shares of the company’s stock after acquiring an additional 720 shares during the quarter. Lantz Financial LLC’s holdings in Sanofi were worth $306,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of SNY. SRS Capital Advisors Inc. increased its stake in Sanofi by 289.1% in the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares during the period. Fairfield Bush & CO. acquired a new position in Sanofi in the 1st quarter valued at $26,000. CoreCap Advisors LLC purchased a new stake in shares of Sanofi during the 4th quarter worth $27,000. Eagle Bay Advisors LLC purchased a new stake in shares of Sanofi during the 2nd quarter worth $28,000. Finally, Disciplined Investments LLC boosted its position in shares of Sanofi by 2,270.8% during the 1st quarter. Disciplined Investments LLC now owns 569 shares of the company’s stock worth $31,000 after purchasing an additional 545 shares in the last quarter. 10.06% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
SNY has been the subject of a number of research analyst reports. Berenberg Bank raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 5th. HSBC started coverage on shares of Sanofi in a research report on Friday, July 14th. They set a “buy” rating for the company. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.50.
Sanofi Stock Performance
SNY traded up $0.27 during trading hours on Tuesday, hitting $54.35. 55,531 shares of the stock were exchanged, compared to its average volume of 1,589,583. The stock has a 50-day simple moving average of $53.22 and a 200-day simple moving average of $53.63. Sanofi has a 12 month low of $36.91 and a 12 month high of $57.82. The stock has a market cap of $137.22 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 1.57 and a beta of 0.57. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.21 and a quick ratio of 0.81.
Sanofi (NASDAQ:SNY – Get Free Report) last issued its earnings results on Friday, July 28th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.07. Sanofi had a return on equity of 27.94% and a net margin of 16.07%. The firm had revenue of $10.85 billion for the quarter, compared to analyst estimates of $11.47 billion. Analysts anticipate that Sanofi will post 4.45 earnings per share for the current year.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- Health Care Stocks Explained: Why You Might Want to Invest
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- Profitably Trade Stocks at 52-Week Highs
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- What is the Australian Securities Exchange (ASX)
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.